PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for people who are un...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cochrane Database Syst Rev
Hlavní autoři: Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Ltd 2020
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094613/
https://ncbi.nlm.nih.gov/pubmed/33078867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky